For the completion, the company has initiated the installation qualification (IQ) validation process through Biopharmax Group, which is handling the build-out of Pluristem’s facility.
Following the successful IQ, an operation qualification (OQ) will be initiated, which marks the final stage of the build-out process.
Once constructed, the new facility will produce commercial grade PLX cells which will complement Pluristem’s current 40,000ft² manufacturing facility.
Pluristem chairman and CEO Zami Aberman said, "We are extremely pleased with the progress of erecting one of the most technological advanced commercial grade cell manufacturing facility in the world."